Celularity Announces FDA Clearance of Investigational New Drug Application (IND) for Natural Killer Cell Therapy CYNK-101 in First-line Advanced Her2/neu Positive Gastric and Gastroesophageal Junction Cancer

NEXT STORY
TRACON Pharmaceuticals Reports Regulatory Approval of Envafolimab in China
PREV STORY
Skylight Health Group to Present at The Benchmark Company’s Discovery One on One Virtual Video Investor Conference
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

KBP Biosciences Announces A Greater Than 10 mm Hg Systolic Blood Pressure Reduction in The BLOCK-CKD Phase 2b Study of KBP-5074 in Advanced Chronic Kidney Disease Patients with Uncontrolled Hypertension as Published in Hypertension

author_avatar
NASDAQ Market News

Trillium Closes US$117 Million Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares

author_avatar
NASDAQ Market News

Pre-Budget Report Release: What’s in it for Students?

Ottawa, ON, Dec. 18, 2017 (GLOBE NEWSWIRE) -- The Standing Committee on Finance (FINA) ...

author_avatar
NASDAQ Market News